克拉斯
免疫系统
癌症研究
基因敲除
结直肠癌
生物
核糖核酸
调节器
肿瘤微环境
环状RNA
长非编码RNA
免疫
免疫耐受
突变
微卫星不稳定性
免疫疗法
免疫沉淀
靶向治疗
癌症
癌变
逃避(道德)
甲基转移酶
免疫学
作者
Seungjae Shin,Seung-Pyo Hong,Seoho Lee,Yeonseo Jang,Jisoo Yang,Jaeik Oh,Dongjun Jang,Soo-Jin Lee,Jiwon Kim,Sang Eun Lee,Yoojin Yang,DoHee Kim,Eunjeong Yang,Seohyeon Park,SaBeen Hwang,Ae Jin Goo,Hae Rim Jung,Yumi Oh,Chang‐Han Lee,Joo‐Youn Cho
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-07-29
卷期号:86 (20): 5184-5204
被引量:1
标识
DOI:10.1158/0008-5472.can-26-0403
摘要
KRAS mutations, present in about 40% of colorectal cancers, are strongly associated with an immunosuppressive tumor microenvironment characterized by restricted immune infiltration and poor responses to immunotherapy. In this study, we found that KRAS mutations remodel the N6-methyladenosine (m6A) epitranscriptome to promote immune evasion. Methylated RNA immunoprecipitation sequencing revealed that KRAS-mutant cells exhibit increased m6A deposition on CD73 mRNA, enhancing its stability through IGF2BP3. TEAD4-dependent recruitment of the METTL3 methyltransferase complex induced the m6A modification, identifying TEAD4 as a spatial regulator of m6A deposition. Functionally, METTL3 knockdown in KRAS-mutant syngeneic tumors suppressed tumor growth and restored antitumor immunity by increasing CD8+ T-cell and NK cell infiltration in a CD73-dependent manner. Moreover, METTL3 inhibition synergized with anti-PD-1 therapy and a CD73 inhibitor to reduce tumor burden. Together, these findings demonstrate that KRAS-driven m6A remodeling is a key mechanism of immune suppression in colorectal cancer and highlight METTL3 as a promising therapeutic target. SIGNIFICANCE: KRAS mutations suppress immune cell infiltration by increasing CD73 expression through m6A reprogramming driven by TEAD4-mediated relocalization of METTL3, providing a targetable axis to promote antitumor immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI